<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04938427</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-935-3002</org_study_id>
    <secondary_id>2021-002481-40</secondary_id>
    <secondary_id>jRCT2051210073</secondary_id>
    <nct_id>NCT04938427</nct_id>
  </id_info>
  <brief_title>A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subjects With Lennox-Gastaut Syndrome (LGS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are:&#xD;
&#xD;
        -  to learn if soticlestat, when given as add-on therapy, reduces the number of major motor&#xD;
           drop seizures in children, teenagers, and adults with Lennox-Gastaut Syndrome.&#xD;
&#xD;
        -  to assess the safety profile of soticlestat when given in combination with other&#xD;
           therapies.&#xD;
&#xD;
      Participants will receive their standard anti-seizure therapy, plus either tablets of&#xD;
      soticlestat or placebo. A placebo looks just like soticlestat but will not have any medicine&#xD;
      in it. Participants will take soticlestat or placebo for 16 weeks, followed by a gradual dose&#xD;
      reduction for 1 week. Then, participants will be followed up for 2 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called soticlestat (TAK-935). Soticlestat will be&#xD;
      assessed for efficacy, safety, and tolerability in pediatric and adult participants with&#xD;
      Lennox-Gastaut syndrome (LGS).&#xD;
&#xD;
      The study will enroll approximately 234 patients. Participants will be randomly assigned (by&#xD;
      chance, like flipping a coin) in a 1:1 ratio to receive standard of care (SOC) plus one of&#xD;
      the following adjunctive therapies which will remain undisclosed to the participant and study&#xD;
      doctor during the study (unless there is an urgent medical need):&#xD;
&#xD;
        1. Soticlestat&#xD;
&#xD;
        2. Placebo (dummy inactive pill - this is a tablet/mini-tablet that looks like the study&#xD;
           drug but has no active ingredient)&#xD;
&#xD;
      Participants will receive soticlestat or matching placebo based on their weight in the 4-week&#xD;
      Titration Period. Following the Titration Period, participants will continue to receive the&#xD;
      same dose in the Maintenance Period. The dose will then be down-tapered.&#xD;
&#xD;
      This multi-center trial will be conducted worldwide. The overall time to participate in the&#xD;
      study will be from 22-25 weeks. Participants will then have an option to either enter the&#xD;
      Open-label Extension (OLE) Study or discontinue. If participants discontinue, they will be&#xD;
      followed-up for safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">March 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 5, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change from Baseline in Major Motor Drop (MMD) Seizure Frequency Per 28 Days During the Full Treatment Period</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>MMD seizure frequency per 28 days is defined as total number of MMD seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline will be defined as (frequency of seizures per 28 days during full Treatment Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change from Baseline in Major Motor Drop (MMD) Seizure Frequency Per 28 Days During the Maintenance Period (EMA Region Specific)</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>MMD seizure frequency per 28 days is defined as total number of MMD seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline will be defined as (frequency of seizures per 28 days during the Maintenance Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100. This outcome measure is European Medicines Agency (EMA) region specific.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders During the Maintenance Period</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>Responders are defined as those with ≥50% reduction from Baseline in MMD seizures during the Maintenance Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders During the Full Treatment Period</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>Responders are defined as those with ≥50% reduction from Baseline in MMD seizures during the full Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Frequency of All Seizures per 28 Days During the Maintenance Period</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>Seizure frequency per 28 days is defined as total number of seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline is defined as (frequency of seizures per 28 days during Maintenance Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in Frequency of All Seizures per 28 Days During the Full Treatment Period</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>Seizure frequency per 28 days is defined as total number of seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline is defined as (frequency of seizures per 28 days during full Treatment Period - frequency of seizures per 28 days at Baseline) divided by the frequency of seizures per 28 days at Baseline multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change from Baseline in MMD Seizure Frequency per 28 Days During the Maintenance Period</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>MMD seizure frequency per 28 days is defined as total number of MMD seizures reported during the period divided by number of days during the period seizures were assessed multiplied by 28. Percent change from Baseline is defined as (frequency of seizures per 28 days during Maintenance Period - frequency of seizures per 28 days at Baseline) divided by frequency of seizures per 28 days at Baseline multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ≤0%, &gt;0% to ≤25%, &gt;25% to ≤50%, &gt;50% to ≤75%, &gt;75% to ≤100% Reduction in MMD Seizure in a Cumulative Response Curve</measure>
    <time_frame>Baseline up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Percentage of MMD Seizure-free Days</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>MMD Seizure-free days will be defined as the number of days the participant remained MMD seizure free after initiation of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Longest MMD Seizure-free Interval</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>Longest MMD Seizure-free Interval will be defined as the longest time period that the participant remained MMD seizure free after initiation of the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days When Rescue Antiseizure Medication (ASM) is Used</measure>
    <time_frame>Baseline up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) Score</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The CGI-I Clinician is a 7-point Likert scale that the investigator uses to rate a participant's change (improvement) in overall seizure control, behavior, safety and tolerability, after the initiation of study drug relative to Baseline (before treatment with study drug). The participant will be rated as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). Higher score will indicate worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Global Impression of Improvement (Care GI-I) Score</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The Care GI-I is a 7-point Likert scale that the caregiver uses to rate improvement in overall seizure control, behavior, safety and tolerability after the initiation of study drug relative to Baseline (before treatment with study drug). The participant will be rated as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). The parent/caregiver will complete the Care GI-I via interview. Higher score will indicate worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I Seizure Intensity and Duration Score</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The CGI-I Seizure Intensity and Duration instrument is used by the parent/caregiver to rate changes in intensity and duration of MMD seizures from the first assessment. The participant's symptoms will be rated on the 7-point scale as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). Higher score will indicate worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I Nonseizure Symptoms Score</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The CGI-I nonseizure symptoms instrument is a series of single-item assessments that the investigator uses to rate improvement in the symptoms and impacts in select nonseizure domains since initiating the study drug. The participant will be rated by the investigator on the 7-point scale as follows: 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), and 7 (very much worse). Higher score will indicate worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Inventory-Disability (QI-Disability) Score</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The QI-Disability tool is a parent/caregiver-reported questionnaire that evaluates quality of life in children with intellectual disabilities. It contains 32 items covering 6 domains of quality of life: physical health, positive emotions, negative emotions, social interaction, leisure and the outdoors, and independence. Scores are from a 5-point Likert scale and then are transformed to a scale of 0 to 100. Possible scores range from 0-100, with higher scores indicating better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Lennox Gastaut Syndrome (LGS)</condition>
  <arm_group>
    <arm_group_label>Soticlestat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants weighing &lt;45 kg: Soticlestat, mini-tablets, at the dose of 40 mg to 200 mg, orally or via gastrostomy tube (G-tube) or percutaneous endoscopic gastrostomy (PEG) tube, twice daily (BID) based on body weight up to 4 weeks in Titration Period. Participants will continue to receive the dose that they are on at the end of the titration period, for 12 weeks in the Maintenance Period. Total duration of the treatment will be up to 16 weeks (Treatment Period). Dose will be tapered down if participants decide to discontinue the treatment.&#xD;
Participants weighing ≥45 kg: Soticlestat mini-tablets or tablets with a starting dose of 100 mg BID followed by 200 mg BID and, then 300 mg BID, up to 4 weeks in Titration Period. Participants will continue to receive 300 mg BID for 12 weeks in the Maintenance Period. Total duration of the treatment will be up to 16 weeks (Treatment Period). Dose will be tapered down if participants decide to discontinue the treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soticlestat placebo-matching mini-tablets or tablets, orally or via G-tube or PEG tube, BID, up to 4 weeks in the Titration Period. Participants will continue to receive the soticlestat placebo-matching mini-tablets or tablets for 12 weeks in the Maintenance Period. The total duration of the treatment will be up to 16 weeks (Treatment Period). Soticlestat matching tapering will be done to maintain the blind if participants decide to discontinue the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Soticlestat</intervention_name>
    <description>Soticlestat mini-tablets or tablets.</description>
    <arm_group_label>Soticlestat</arm_group_label>
    <other_name>TAK-935</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Soticlestat placebo-matching mini-tablets or tablets.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Has documented clinical diagnosis of Lennox-Gastaut Syndrome (LGS).&#xD;
&#xD;
          2. Has ≥8 major motor drop (MMD) seizures each month in the 3 months prior to Screening&#xD;
             based on the historical information and has ≥8 MMD seizures per 28 days during the 4&#xD;
             to 6 week prospective Baseline Period.&#xD;
&#xD;
          3. Weighs ≥10 kg at the Screening Visit (Visit 1).&#xD;
&#xD;
          4. Failure to control seizures despite appropriate trials of at least 2 anti-seizure&#xD;
             medications (ASMs) based on historical information, and is currently on an&#xD;
             anti-seizure therapy or other treatment options considered as standard of care (SOC).&#xD;
&#xD;
          5. Currently taking 0 to 3 ASMs at stable doses for at least 4 weeks before the Screening&#xD;
             Visit (Visit 1); ASM dosing regimen must remain constant throughout the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Admitted to a medical facility and intubated for treatment of status epilepticus 2 or&#xD;
             more times in the 3 months immediately before Screening (Visit 1). Status epilepticus&#xD;
             is defined as continuous seizure activity lasting longer than 5 minutes or repeated&#xD;
             seizures without return to Baseline in between seizures.&#xD;
&#xD;
          2. Unstable, clinically significant neurologic (other than the disease being studied),&#xD;
             psychiatric, cardiovascular, ophthalmologic, pulmonary, hepatic, renal, metabolic,&#xD;
             gastrointestinal, urologic, immunologic, hematopoietic, endocrine disease, malignancy&#xD;
             including progressive tumors, or other abnormality that may impact the ability to&#xD;
             participate in the study or that may potentially confound the study results. It is the&#xD;
             responsibility of the investigator to assess the clinical significance; however,&#xD;
             consultation with the medical monitor may be warranted.&#xD;
&#xD;
          3. Considered by the investigator to be at imminent risk of suicide or injury to self,&#xD;
             others, or property, or the participant has attempted suicide within 12 months before&#xD;
             the Screening Visit (Visit 1). Participants who have positive answers on item numbers&#xD;
             4 or 5 on the Columbia suicide severity rating scale (C-SSRS) before&#xD;
             randomization/dosing (Visit 2) are excluded. This scale will only be administered to&#xD;
             participants aged ≥6 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>602-933-0970</phone>
      <email>awilfong@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Angus Wilfong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>415-353-8440</phone>
      <email>joseph.sullivan@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Children's Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>720-777-6895</phone>
      <email>charuta.joshi@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Charuta Joshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Neurology PA</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>407-293-1122</phone>
      <email>rgdavis@pediatricneurologypa.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Integrative Research Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>678-705-7341</phone>
      <email>rflamini@pandaneuro.com</email>
    </contact>
    <investigator>
      <last_name>Julio Flamini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics - (CRS)</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>319-384-5437</phone>
      <email>michael-ciliberto@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Ciliberto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midatlantic Epilepsy and Sleep Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>301-530-9744</phone>
      <email>kleinp@epilepsydc.com</email>
    </contact>
    <investigator>
      <last_name>Pavel Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Epilepsy Group PA</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>651-241-5290</phone>
      <email>nagarwal@mnepilepsy.net</email>
    </contact>
    <investigator>
      <last_name>Nitin Agarwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Neurology and Neurosurgery at Saint Barnabas, LLC</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>973-971-5700</phone>
      <email>rmahalingam@inst-neuro.com</email>
    </contact>
    <investigator>
      <last_name>Rajeshwari Mahalingam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Comprehensive Epilepsy Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>646-558-0842</phone>
    </contact>
    <investigator>
      <last_name>Orrin Devinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>215-590-1719</phone>
      <email>marshe@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Marsh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>215-955-1222</phone>
      <email>michael.sperling@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Sperling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Children Hospital - PIN</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>843-792-3221</phone>
      <email>halfordj@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Halford</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center - Jane and John Justin Neurosciences Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>682-885-2500</phone>
      <email>scott.perry@cookchildrens.org</email>
    </contact>
    <investigator>
      <last_name>Michael Perry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah - Primary Children's Hospital - PPDS</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>801-587-7575</phone>
      <email>matthew.sweney@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Sweney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>206-987-2708</phone>
      <email>russ.saneto@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Russell Saneto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61293821658</phone>
      <email>john.lawson@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>John Lawson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg West</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61390357112</phone>
      <email>i.scheffer@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Ingrid Scheffer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+61390762000</phone>
      <email>te.obrien@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>Terence OBrien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3234660610</phone>
      <email>berten.ceulemans@uza.be</email>
    </contact>
    <investigator>
      <last_name>Berten Ceulemans</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Neurologique William Lennox</name>
      <address>
        <city>Ottignies</city>
        <state>Brabant Wallon</state>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3210430211</phone>
      <email>pascal.vrielynck@chnwl.be</email>
    </contact>
    <investigator>
      <last_name>Pascal Vrielynck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire des Enfants Reine Fabiola</name>
      <address>
        <city>La Louviere</city>
        <state>Hainaut</state>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3224773174</phone>
      <email>alec.aeby@huderf.be</email>
    </contact>
    <investigator>
      <last_name>Alec Aeby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Child and Family Research Institute</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 0B3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(604) 875-2612</phone>
      <email>cyrus.boelman@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Cyrus Boelman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>(416) 813-7037</phone>
      <email>cecil.hahn@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Cecil Hahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613701398992</phone>
      <email>jiangyuwu@bjmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yuwu Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital,Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+861059616161</phone>
      <email>13910150389@163.com</email>
    </contact>
    <investigator>
      <last_name>Fang Fang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+868888888888</phone>
      <email>neurojiang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Li Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Guangzhou Medical Univeristy</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+862034152626</phone>
      <email>wpliao@163.net</email>
    </contact>
    <investigator>
      <last_name>Wei-Ping Liao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Women And Children's Medical Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510623</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8618902268798</phone>
      <email>gzchcwx@126.com</email>
    </contact>
    <investigator>
      <last_name>Wen-Xiong Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Children's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518026</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8675583936101</phone>
      <email>liaojianxiang@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Jianxiang Liao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuhan Childrens hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613971616910</phone>
      <email>bloveriver@163.com</email>
    </contact>
    <investigator>
      <last_name>Dan Sun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410078</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613548966986</phone>
      <email>pengjing4346@163.com</email>
    </contact>
    <investigator>
      <last_name>Jing Peng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial Children's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613077900710</phone>
      <email>zhongjm@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianmin Zhong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8613578652528</phone>
      <email>jackyliangjm@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianmin Liang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8618930590051</phone>
      <email>chenyc@shchildren.com.cn</email>
    </contact>
    <investigator>
      <last_name>Yucai Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+8618017591161</phone>
      <email>szzhou@shmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Shui-Zhen Zhou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33241354445</phone>
      <email>sylvie.nguyenthetich@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvie Nguyen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33144494854</phone>
      <email>rima.nabbout@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Rima El Nabbout-Tarantino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Debre</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+33140033667</phone>
      <email>stephane.auvin@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Stephane Auvin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Attikon University General Hospital</name>
      <address>
        <city>Chaidari</city>
        <state>Attiki</state>
        <zip>124 62</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302105831269</phone>
      <email>argidino@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Argirios Dinopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Larissa</name>
      <address>
        <city>Larisa</city>
        <zip>413 35</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302413501137</phone>
      <email>edar@med.uth.gr</email>
    </contact>
    <investigator>
      <last_name>Efthimios Dardiotis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 42</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+302310892437</phone>
      <email>dizafeir@auth.gr</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Zafeiriou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem</name>
      <address>
        <city>Pecs</city>
        <state>Baranya</state>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3672535900</phone>
      <email>hollody.katalin@pte.hu</email>
    </contact>
    <investigator>
      <last_name>Katalin Hollody</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda Gyermekkorhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1143</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+3614222873</phone>
      <email>fog.andras@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andras Fogarasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orszagos Mentalis, Ideggyogyaszati es Idegsebeszeti Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+36306894111</phone>
      <email>fabo.daniel@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Fabo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST di Mantova - Azienda Ospedaliera Carlo Poma</name>
      <address>
        <city>Mantova</city>
        <state>Lombardia</state>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390376201373</phone>
      <email>francesca.beccaria@asst-mantova.it</email>
    </contact>
    <investigator>
      <last_name>Francesca Beccaria</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST di Pavia - Fondazione Istituto Neurologico Mondino IRCCS</name>
      <address>
        <city>Pavia</city>
        <state>Lombardia</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390382380289</phone>
      <email>valentina.degiorgis@mondino.it</email>
    </contact>
    <investigator>
      <last_name>Valentina De Giorgis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria A Meyer - INCIPIT - PIN</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+390555662573</phone>
      <email>renzo.guerrini@meyer.it</email>
    </contact>
    <investigator>
      <last_name>Renzo Guerrini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukuoka Children's Hospital</name>
      <address>
        <city>Fukuoka-Shi</city>
        <state>Hukuoka</state>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81926827000</phone>
      <email>kira.r@fcho.jp</email>
    </contact>
    <investigator>
      <last_name>Ryutaro Kira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kumamoto-Ezuko Medical Center for The Severely Disabled</name>
      <address>
        <city>Kumamoto-Shi</city>
        <state>Kumamoto</state>
        <zip>862-0947</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81963700501</phone>
      <email>T-ishitsu@ezuko.jp</email>
    </contact>
    <investigator>
      <last_name>Takateru Ishitsu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagasaki Medical Center</name>
      <address>
        <city>Omura-Shi</city>
        <state>Nagasaki</state>
        <zip>856-0835</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81957523121</phone>
      <email>honda.ryoko.gu@mail.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Ryoko Honda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nishi-Niigata Chuo National Hospital</name>
      <address>
        <city>Niigata-Shi</city>
        <state>Niigata</state>
        <zip>950-2074</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81252653171</phone>
      <email>tohyama.jun.um@mail.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Jun Tohyama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama-Shi</city>
        <state>Okayama</state>
        <zip>700-0914</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81862357991</phone>
      <email>k_koba@md.okayama-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Katsuhiro Kobayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yasuhara Childrens Clinic</name>
      <address>
        <city>Neyagawa-Shi</city>
        <state>Osaka</state>
        <zip>572-0085</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81728322211</phone>
      <email>akihiro-yasuhara@car.ocn.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Akihiro Yasuhara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka-Shi</city>
        <state>Osaka</state>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81669291221</phone>
      <email>h-kawawaki@hospital.city.osaka.jp</email>
    </contact>
    <investigator>
      <last_name>Hisashi Kawawaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita-Shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81668795111</phone>
      <email>nabatames@ped.med.osaka-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Shin Nabatame</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shizuoka Institute of Epilepsy and Neurological Disorders</name>
      <address>
        <city>Shizuoka-Shi</city>
        <state>Sizuoka</state>
        <zip>420-0953</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81542455446</phone>
      <email>s.hizuokasan3@googlemail.com</email>
    </contact>
    <investigator>
      <last_name>Tokito Yamaguchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center of Neurology and Psychiatry</name>
      <address>
        <city>Kodaira-Shi</city>
        <state>Tokyo</state>
        <zip>187-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81423462190</phone>
      <email>nakagawa@ncnp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Eiji Nakagawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Medical University Hospital</name>
      <address>
        <city>Nagakute</city>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+81561623311</phone>
      <email>okumura.akihisa.479@mail.aichi-med-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Akihisa Okumura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+37129535342</phone>
      <email>dr.rozentals@inbox.lv</email>
    </contact>
    <investigator>
      <last_name>Guntis Rozentals</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kempenhaeghe - PPDS</name>
      <address>
        <city>Heeze</city>
        <state>Noord-Brabant</state>
        <zip>5591 VE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+31402279203</phone>
      <email>majoiem@kempenhaeghe.nl</email>
    </contact>
    <investigator>
      <last_name>Marian Majoie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stichting Epilepsie Instellingen Nederland</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8025 BV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+31683709913</phone>
      <email>bgunning@sein.nl</email>
    </contact>
    <investigator>
      <last_name>Boudewijn Gunning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Plejady</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-363</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48123535555</phone>
      <email>marta.zolnowska@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta Zolnowska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dzieciecy Szpital Kliniczny im. Jozefa Polikarpa Brudzinskiego w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+488888888888</phone>
      <email>sergiusz.jozwiak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sergiusz Jozwiak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48583492396</phone>
      <email>mmazur@gumed.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Maria Mazurkiewicz-Beldzinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+48618691613</phone>
      <email>bstein@ump.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Barbara Steinborn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medical University n.a. N.I.Pirogov</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79161454795</phone>
      <email>zavadenko@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Nikolay Zavadenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Russian National Research Medical University n.a. N.I.Pirogov</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79161888426</phone>
      <email>edbelous56@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Elena Belousova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UGMK-Zdorojie, LLC</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+73432830808</phone>
      <email>trtomenko@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Tatiana Tomenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krasnoyarsk State Medical University n.a. V.F. Voyno-Ysenetskiy</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79080160312</phone>
      <email>mart2802@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Diana Dmitrenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tyumen State Medical Academy</name>
      <address>
        <city>Tyumen</city>
        <zip>625039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+79829722309</phone>
      <email>olga-rakh@yandex.ru</email>
    </contact>
    <investigator>
      <last_name>Olga Rakhmanina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic for Neurology and Psychiatry for Children and Youth</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+381638679625</phone>
      <email>milan.borkovic.npk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Milan Borkovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mother and Child Health Care Institute of Serbia Dr Vukan Cupic</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+381642612210</phone>
      <email>ruzica.kravljanac@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ruzica Kravljanac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinical Center Nis</name>
      <address>
        <city>Nis</city>
        <zip>18 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+381642572634</phone>
      <email>tosic.tatjana@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tatjana Tosic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children and Youth Health Care Institute of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <zip>401136</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+38121424385</phone>
      <email>mkp.marija@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marija Knezevic-Pogancev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34948255004251</phone>
      <email>rsanchezc@unav.es</email>
    </contact>
    <investigator>
      <last_name>Rocio Sanchez-Carpintero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34934894257</phone>
      <email>mtoledo@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Manuel Toledo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vithas La Salud</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34958023352</phone>
      <email>jucasan9@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Sanchez Alvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+34961244161</phone>
      <email>vevillanuevah@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Vicente Villanueva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Municipal Institution Dnipropetrovsk Regional Children Clinical Hospital of DRC</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovs'ka Oblast</state>
        <zip>49038</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+380676220775</phone>
      <email>grial2401@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alla Kyrychenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Enterprise City Childrens Clinical Hospital #5 of DCC</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovs'ka Oblast</state>
        <zip>49101</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+380567446150</phone>
      <email>iryna.maked@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Iryna Makedonska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise Iv-Frank Regional Childrens Clinical Hosp of Iv-Frank RC</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+380342527878</phone>
      <email>delwa@ukr.net</email>
    </contact>
    <investigator>
      <last_name>Dmytro Delva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CNPE Clinical Hospital Psychiatry of the Executive Body of the Kyiv City Council KCSA</name>
      <address>
        <city>Kyiv</city>
        <zip>04080</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+380679904374</phone>
      <email>vkharytonov69@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Volodymyr Kharytonov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SI Ukr. Med. Rehabilitation Center For Children With Organic Injury of Nervous System of MoH of Ukr</name>
      <address>
        <city>Kyiv</city>
        <zip>04209</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>+380444121068</phone>
      <email>ukrmedcentr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Volodymyr Martyniuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/60e30ebd1f1122001e30a940</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lennox Gastaut Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

